Table 3.

Summary of outcomes according to mRECIST criteria

Main outcome	N (%)
Best tumor response
Complete response (CR)	6 (13.6%)
Partial response (PR)	12 (27.3%)
Stable disease (SD)	10 (22.7%)
Progressive disease (PD)	16 (36.4%)
DCR	21 (63.6%)
ORR	18 (40.9%)
Median OS (months)	27.0 ± 5.8
Median PFS (months)	15.0 ± 2.9
1-year OS rate	83.6% ± 5.7%
2-year OS rate	71.3% ± 7.5%
3-year OS rate	39.0% ± 9.6%
1-year PFS rate	77.0% ± 6.4%
2-year PFS rate	63.9% ± 7.5%
3-year PFS rate	38.0% ± 8.9%

DCR disease control rate, ORR objective response rate, OS overall survival, PFS progression-free survival